Vytrus Biotech (FRA:V5P) Total Current Assets: €5.39 Mil (As of Dec. 2025)


FRA:V5P Vytrus Biotech SA FRA:V5P
63 GF Score
Price €16.70
GF Value €6.81
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Vytrus Biotech Total Current Assets?

Vytrus Biotech FRA:V5P -2.34% 63 Total Current Assets is €5.39 Mil as of Dec. 2025. GuruFocus rates FRA:V5P with a GF Score™ of 63/100 and a GF Value™ of €6.81 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Vytrus Biotech's total current assets for the quarter that ended in Dec. 2025 was €5.39 Mil.

Vytrus Biotech  (FRA:V5P) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Vytrus Biotech's Liquidation Value for the quarter that ended in Dec. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=3.377-4.355+0.75 * 0.982+0.5 * 0.623
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vytrus Biotech Total Current Assets Related Terms

Vytrus Biotech Total Current Assets Historical Data

* Premium members only.

The historical data trend for Vytrus Biotech's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vytrus Biotech Total Current Assets Chart

Vytrus Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Assets
Get a 7-Day Free Trial 1.82 1.68 2.45 3.79 5.39

Vytrus Biotech Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.45 3.53 3.79 5.22 5.39
FRA:V5P
63GF Score
Vytrus Biotech SA FRA:V5P
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vytrus Biotech Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Vytrus Biotech's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=3.377+1.374+0.623+0.015000000000001
=5.39

Vytrus Biotech's Total Current Assets for the quarter that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=3.377+1.374+0.623+0.015000000000001
=5.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of €5.39 Mil mean?
Vytrus Biotech (FRA:V5P) has a Total Current Assets of €5.39 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Vytrus Biotech and its competitors.
Is Vytrus Biotech's Total Current Assets too high?
Vytrus Biotech's current Total Current Assets is €5.39 Mil. Overall, Vytrus Biotech has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Total Current Assets compare to VRTX and REGN?
Vytrus Biotech's Total Current Assets of €5.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Vytrus Biotech and its competitors. Vytrus Biotech's current Total Current Assets is €5.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (FRA:V5P) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.81, compared to a current price of €16.70 — trading 145.2% above its estimated fair value. The current Total Current Assets is €5.39 Mil. Vytrus Biotech's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Vytrus Biotech (FRA:V5P), the current Total Current Assets is €5.39 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vytrus Biotech (FRA:V5P) Overvalued in 2026?

Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued. The current stock price of €16.70 is trading 145.2% above its estimated GF Value™ of €6.81. GuruFocus considers Vytrus Biotech to be Significantly Overvalued.

Key valuation signals for FRA:V5P:

  • Total Current Assets: €5.39 Mil
  • GF Value™: €6.81 vs. price of €16.70 (145.2% above fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the FRA:V5P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vytrus Biotech Business Description

Other Exchanges VYT:Spain
Address Sant Gaieta 121, 2nd Floor, Terrassa, Barcelona, ESP, 08221
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
63GF Score

Get the complete analysis for FRA:V5P

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.70
Price
€6.81
GF Value